actinomycin C3: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 20055431 |
| MeSH ID | M0055218 |
| Synonym |
|---|
| nsc-87222 |
| 2a-d-alloisoleucine-2b-d-alloisoleucine actinomycino-d |
| aurathin-a3 |
| ay 3 |
| nsc 87222 |
| actinomycin ay1 |
| actinomycin d, 2(sup a)-d-alloisoleucine-2(sup b)-d-alloisoleucine- |
| 2104-l-i |
| actinomycin i3 |
| actinomycin c3 |
| 6156-47-4 |
| unii-6z5ds38j6f |
| 6z5ds38j6f , |
| actinomycin d, 2a-d-alloisoleucine-2b-d-alloisoleucine- |
| 3h-phenoxazine-1,9-dicarboxamide, 2-amino-n,n'-bis(hexadecahydro-2,5,9-trimethyl-6-(1-methylethyl)-13-(1-methylpropyl)-1,4,7,11,14-pentaoxo-1h-pyrrolo(2,1-i)(1,4,7,10,13)oxatetraazacyclohexadecin-10-yl)-4,6-dimethyl-3-oxo- |
| DTXSID30873421 |
| Q27265752 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.87) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||